ALPS Advisors’s Tourmaline Bio TRML Stock Holding History

ALPS Advisors’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,465	Closed	-$596K	–	1083
2025 Q3	$596K	Sell	12,465 -1,381	-10%	-$38.3K	﹤0.01%	635
2025 Q2	$221K	Sell	13,846 -3,655	-21%	-$59.2K	﹤0.01%	1002
2025 Q1	$266K	Sell	17,501 -3,234	-16%	-$51.8K	﹤0.01%	932
2024 Q4	$421K	Buy	20,735 +962	+5%	+$24.2K	﹤0.01%	668
2024 Q3	$508K	Sell	19,773 -216	-1%	-$3.6K	﹤0.01%	606
2024 Q2	$257K	Buy	+19,989	New	+$322K	﹤0.01%	922

ALPS Advisors's TRML Position: Q4 2025 in Review

ALPS Advisors sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 12,465 shares — an estimated $596K sold.

ALPS Advisors first reported a position in TRML in Q2 2024 and held it in 6 quarters. The position peaked at $596K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

ALPS Advisors reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
ALPS Advisors sold 12,465 Tourmaline Bio shares in Q4 2025, an estimated $596K.
ALPS Advisors first reported a position in Tourmaline Bio in Q2 2024 and held it in 6 quarters.
ALPS Advisors's Tourmaline Bio position peaked at $596K in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.